Review ArticlesSpectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid NeoplasmsXie, Zhuoer MD, MS∗; Chen, Evan C. MD†; Mendez, Lourdes M. MD, PhD‡; Komrokji, Rami MD∗; Zeidan, Amer M. MBBS, MHS‡ Author Information From the ∗Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, FL †Adult Leukemia Program, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA ‡Section of Hematology, Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT. Z.X. and E.C.C. are co–first authors with equal contribution. Author Contributions: Z.X. and E.C.C. contributed equally to this work. All authors wrote, reviewed, edited the manuscript, and approved the final version. Conflicts of Interest and Source of Funding: Z.X., E.C.C., and L.M.M. declare no conflict of interest. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene/Cardiff Oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics; participated in advisory boards and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, and Tyme; and served on clinical trial committees for Novartis, Abbvie, Geron, and Celgene/BMS. None of these relationships were related to this work. A.M.Z. is a Leukemia and Lymphoma Society Scholar in Clinical Research. R.K. consulted for Abbvie: speaker's bureau, advisory board; BMS: research grant, advisory board; CTI Biopharma: speaker's bureau, advisory board; Geron: consultancy; Jazz: speaker's bureau, advisory board; Novartis: advisory board; Pharma Essentia: speaker's bureau, advisory board; Servio: speaker's bureau, advisory board; Taiho: advisory board. All figures were created with BioRender.com. Reprints: Amer M. Zeidan, MBBS, MHS, Section of Hematology, Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine, 37 College St, First floor, New Haven, CT 06510. E-mail: [email protected]. The Cancer Journal 29(3):p 130-137, 5/6 2023. | DOI: 10.1097/PPO.0000000000000656 Buy Metrics Abstract Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH management and research. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.